Home Featured 2

Featured 2

Featured posts

Random

Q&A with Lead ALCHEMIST Investigator, Dr. Ramaswamy Govindan

lungcanc

A Cloud-Based Computerized System for the Korean Lung Cancer Screening Project

Smoking Cessation Prior to Lung Cancer Surgery

U.S. Drug Approvals: 2010 – 2020

The Changing the Landscape of Tobacco Products: Potential Effects of ENDS and HTPs

Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data

lungcanc

Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

lungcanc

Smoking Cessation Prior to Lung Cancer Surgery

lungcanc

IASLC Journals Share Exciting Milestones on Metrics Journeys

lungcanc

Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for...

lungcanc

Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization

lungcanc

Sublobar Resections for Early Lung Cancer

lungcanc

On the Backs of Specialists: LDCT Screening Has Heightened the Importance...

lungcanc

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry...

lungcanc

PCI Decreases the Risk of Brain Metastases in Patients with Locally...

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib